Search - tctmd.com

Displaying 61 - 80 of 109

Sort: Relevancy | Date

News Conference News EuroPCR 2018

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Caitlin E. Cox

May 23, 2018

Presentation EuroPCR 2018

Anatomical Predictors of Stroke Prevention During Transcatheter Aortic Valve Implantation: The SENTINEL Trial

Presenter: Hasan Jilaihawi

May 23, 2018

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Shelley Wood

May 17, 2018

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Conference News EuroPCR 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

Michael O'Riordan

May 26, 2017

News Conference News EuroPCR 2017

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Michael O'Riordan

May 24, 2017

News Conference News EuroPCR 2017

Transradial PCI in ACS Reduces Risk of Acute Kidney Injury

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

News Conference News EuroPCR 2017

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

Yael L. Maxwell

May 17, 2017

REPRISE III: Lotus Valve Matches CoreValve in First Head-to-Head TAVR Trial

News Conference News EuroPCR 2017

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

Shelley Wood

May 16, 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After ACS Saves Money, Prevents Bleeding

News Conference News EuroPCR 2017

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

Yael L. Maxwell

May 16, 2017

News Conference News EuroPCR 2016

‘Europe Isn’t Waiting’: MitraClip Moves Into New Niches, Big and Small

Shelley Wood

May 26, 2016

News Conference News EuroPCR 2016

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Michael O'Riordan

May 23, 2016

News Conference News EuroPCR 2016

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Yael L. Maxwell

May 20, 2016

News Conference News EuroPCR 2016

Planned MitraClip Implantation Safe, Feasible After TAVR, Small Series Suggests

Yael L. Maxwell

May 20, 2016

Presentation EuroPCR 2016

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Presenter: Jens Erik Nielsen-Kudsk

May 20, 2016

News Conference News EuroPCR 2016

Embolic Protection in TAVR: If, When, What, and How Debated as Trials Wrap Up

Shelley Wood

May 20, 2016

Presentation EuroPCR 2016

A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement

Presenter: Alexandra Lansky

May 20, 2016

Advertisement

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Anatomical Predictors of Stroke Prevention During Transcatheter Aortic Valve Implantation: The SENTINEL Trial

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure

Transradial PCI in ACS Reduces Risk of Acute Kidney Injury

More Early Stroke With SAVR Than TAVR in SURTAVI

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

The ARTE of Antiplatelet Therapy After TAVR: Bleeding Greater with Clopidogrel Plus Aspirin vs Aspirin Alone

REPRISE III: Lotus Valve Matches CoreValve in First, Large Head-to-Head TAVR Trial

TOPIC: Replacing P2Y12 Inhibitors With Clopidogrel 1 Month After PCI Saves Money, Prevents Bleeding in ACS

‘Europe Isn’t Waiting’: MitraClip Moves Into New Niches, Big and Small

Studies Highlight Permanent Pacemaker Rates Among New-Generation TAVR Devices

Valvular Interventions for the Asymptomatic and Low Risk: Coming Soon to a Cath Lab Near You?

Planned MitraClip Implantation Safe, Feasible After TAVR, Small Series Suggests

LAA Occlusion vs Standard Care In Patients With Atrial Fibrillation And Intracerebral Hemorrhage

Embolic Protection in TAVR: If, When, What, and How Debated as Trials Wrap Up

A Patient Level Pooled Analysis of NeuroProtection with the TriGuard Embolic DEFLECTion Device Compared to Unprotected Transcatheter Aortic Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content